{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:46:54Z","timestamp":1787687214355,"version":"build-2784847793"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.berh.2021.101684","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T08:14:04Z","timestamp":1620202444000},"page":"101684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Botulinum toxin in the management of primary and secondary Raynaud's phenomenon"],"prefix":"10.1016","volume":"35","author":[{"given":"Daniel","family":"Ennis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zareen","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.berh.2021.101684_bib1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1191\/0961203304lu1072oa","article-title":"Impaired brachial artery endothelium dependent flow mediated dilation in systemic lupus erythematosus: preliminary observations","volume":"13","author":"Johnson","year":"2004","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.berh.2021.101684_bib2","first-page":"2347","article-title":"Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension","volume":"33","author":"Johnson","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2021.101684_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0012-3692(15)51873-4","article-title":"Thrombotic arteriopathy and anticoagulation in pulmonary hypertension","volume":"130","author":"Johnson","year":"2006","journal-title":"Chest"},{"issue":"9374","key":"10.1016\/j.berh.2021.101684_bib4","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(03)13646-X","article-title":"Raynaud's disease","volume":"361","author":"Bowling","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/acr.20684","article-title":"Validation of potential classification criteria for systemic sclerosis","volume":"64","author":"Johnson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"11","key":"10.1016\/j.berh.2021.101684_bib6","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2021.101684_bib7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","article-title":"Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis","volume":"73","author":"Minier","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2021.101684_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11926-015-0506-3","article-title":"New ACR EULAR guidelines for systemic sclerosis classification","volume":"17","author":"Johnson","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2015.04.005","article-title":"Management of Raynaud phenomenon and digital ulcers in scleroderma","volume":"41","author":"Cappelli","year":"2015","journal-title":"Rheum Dis Clin N Am"},{"issue":"9","key":"10.1016\/j.berh.2021.101684_bib10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101684_bib11","first-page":"1117","article-title":"Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases","volume":"33","author":"Johnson","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101684_bib12","first-page":"1123","article-title":"Scleroderma: health services utilization from patients' perspective","volume":"33","author":"Johnson","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101684_bib13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud's phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.mib.2012.05.005","article-title":"Learning from the past: historical aspects of bacterial toxins as pharmaceuticals","volume":"15","author":"Pellett","year":"2012","journal-title":"Curr Opin Microbiol"},{"issue":"10","key":"10.1016\/j.berh.2021.101684_bib15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.bjps.2012.04.016","article-title":"Botulinum neurotoxin A: a review","volume":"65","author":"Berry","year":"2012","journal-title":"J\u00a0Plast Reconstr Aesthetic Surg"},{"issue":"Pt 1","key":"10.1016\/j.berh.2021.101684_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/eye.1988.5","article-title":"Clostridium botulinum toxins: nature and preparation for clinical use","volume":"2","author":"Melling","year":"1988","journal-title":"Eye"},{"issue":"11","key":"10.1016\/j.berh.2021.101684_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","article-title":"Botulinum and tetanus neurotoxins: structure, function and therapeutic utility","volume":"27","author":"Turton","year":"2002","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cps.2011.03.010","article-title":"An overview of botulinum toxins: past, present, and future","volume":"38","author":"Cartee","year":"2011","journal-title":"Clin Plast Surg"},{"issue":"5","key":"10.1016\/j.berh.2021.101684_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.toxicon.2008.11.018","article-title":"Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel","volume":"54","author":"Montal","year":"2009","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2014.195","article-title":"A\u00a0vascular mechanistic approach to understanding Raynaud phenomenon","volume":"11","author":"Flavahan","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101684_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hcl.2014.09.003","article-title":"The role of botulinum toxin in vasospastic disorders of the hand","volume":"31","author":"Neumeister","year":"2015","journal-title":"Hand Clin"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":"Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases","volume":"53","author":"Cote","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.berh.2021.101684_bib23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum toxin B injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","author":"Motegi","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.berh.2021.101684_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2362.2004.01324.x","article-title":"Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study","volume":"34","author":"Sycha","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"S3","key":"10.1016\/j.berh.2021.101684_bib25","first-page":"275","article-title":"Raynaud's phenomenon: treatment with botulinum toxin","volume":"64","author":"Stadlmaier","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2021.101684_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.prs.0000244860.00674.57","article-title":"Management of vasospastic disorders with botulinum toxin A","volume":"119","author":"Van Beek","year":"2007","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhsa.2008.11.026","article-title":"Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon","volume":"34","author":"Fregene","year":"2009","journal-title":"J\u00a0Hand Surg"},{"key":"10.1016\/j.berh.2021.101684_bib28","first-page":"ii52","article-title":"Sustainable improvement can be achieved with intradermal injections of botulinum toxin a (BTX-A) in a patient with limited scleroderma: 3-years follow-up","volume":"2","author":"Tosounidou","year":"2012","journal-title":"Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2021.101684_bib29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.anplas.2011.11.001","article-title":"Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis","volume":"58","author":"Serri","year":"2013","journal-title":"Ann Chir Plast Esthet"},{"issue":"6\u20137","key":"10.1016\/j.berh.2021.101684_bib30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.annder.2014.03.003","article-title":"Improvement of idiopathic Raynaud's phenomenonfollowing local infusion of botulinum toxin","volume":"141","author":"Roguedas","year":"2014","journal-title":"Ann Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.berh.2021.101684_bib31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.piel.2015.02.004","article-title":"Botulinum toxin treatment of severe Raynaud's phenomenon","volume":"30","author":"Valdeolivas-Casillas","year":"2015","journal-title":"Piel"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/ajd.12326","article-title":"Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment","volume":"56","author":"Zhao","year":"2015","journal-title":"Australas J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2021.101684_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study","volume":"43","author":"Motegi","year":"2016","journal-title":"J\u00a0Dermatol"},{"issue":"Supplement 2","key":"10.1016\/j.berh.2021.101684_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/annrheumdis-2016-eular.2176","article-title":"The use of a dorsal approach for the injection of botulinum toxin a in the treatment of raynauds phenomenon secondary to scleroderma","volume":"75","author":"Dhaliwal","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2021.101684_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/RHU.0000000000000450","article-title":"Iatrogenic Thenar Eminence atrophy after Botox A injection for secondary Raynaud phenomenon","volume":"22","author":"Eickhoff","year":"2016","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2021.101684_bib36","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2021.101684_bib37","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/iwj.12742","article-title":"Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case","volume":"14","author":"Blaise","year":"2017","journal-title":"Int Wound J"},{"issue":"4","key":"10.1016\/j.berh.2021.101684_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ced.13333","article-title":"Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin","volume":"43","author":"Garrido-Rios","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2021.101684_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-219348","article-title":"The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes","author":"Dhaliwal","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"Supplement 2","key":"10.1016\/j.berh.2021.101684_bib40","first-page":"S47","article-title":"Infiltration of botulinum toxin in Raynaud's phenomenon","volume":"34","author":"Gonzalez Lago","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.berh.2021.101684_bib41","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/annrheumdis-2015-eular.5148","article-title":"Role and efficacy of botulinum toxin type a in the management of raynauds phenomenon secondary to systemic connective tissue disorders","volume":"2","author":"Sriram","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2021.101684_bib42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PRS.0b013e3181a80576","article-title":"Botox therapy for ischemic digits","volume":"124","author":"Neumeister","year":"2009","journal-title":"Plast Reconstr Surg"},{"issue":"12","key":"10.1016\/j.berh.2021.101684_bib43","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jhsa.2010.09.019","article-title":"Botulinum toxin type a in the treatment of Raynaud's phenomenon","volume":"35","author":"Neumeister","year":"2010","journal-title":"J\u00a0Hand Surg"},{"issue":"5","key":"10.1016\/j.berh.2021.101684_bib44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaad.2013.06.029","article-title":"A\u00a0pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon","volume":"69","author":"Jenkins","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.berh.2021.101684_bib45","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1753193413516242","article-title":"A\u00a0prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma","volume":"39","author":"Uppal","year":"2014","journal-title":"J\u00a0Hand Surg Eur"},{"issue":"7","key":"10.1016\/j.berh.2021.101684_bib46","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/rheumatology\/kew225","article-title":"Management of Raynaud's digital ulcer with interdigital Botulinum toxin A injection","volume":"55","author":"Navarro","year":"2016","journal-title":"Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/1346-8138.14140","article-title":"Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary","volume":"45","author":"Motegi","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"7","key":"10.1016\/j.berh.2021.101684_bib48","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10072-015-2084-6","article-title":"Treatment of Raynaud's phenomenon with botulinum toxin type A","volume":"36","author":"Zhang","year":"2015","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.berh.2021.101684_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2310\/7750.2008.07044","article-title":"Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type a treatment","volume":"12","author":"Kossintseva","year":"2008","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.berh.2021.101684_bib50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archdermatol.2011.1144","article-title":"Botulinum toxin-A for the treatment of Raynaud syndrome","volume":"148","author":"Smith","year":"2012","journal-title":"Arch Dermatol"},{"issue":"3 Suppl","key":"10.1016\/j.berh.2021.101684_bib51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.prs.0000444918.38206.74","article-title":"Abstract 5: a 28-day prospective, randomized, double-blind, placebo controlled clinical trial of botulinum toxin type A for Raynaud's phenomen","volume":"133","author":"Webb","year":"2014","journal-title":"Plast Reconstr Surg"},{"issue":"40","key":"10.1016\/j.berh.2021.101684_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005092","article-title":"A\u00a0case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.berh.2021.101684_bib53","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2009.107706","article-title":"The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial","volume":"69","author":"Khanna","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2021.101684_bib54","first-page":"1038","article-title":"Development of the QuickDASH: comparison of three item-reduction approaches","volume":"87","author":"Beaton","year":"2005","journal-title":"J\u00a0Bone Jt Surg"},{"issue":"6","key":"10.1016\/j.berh.2021.101684_bib55","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0363-5023(10)80065-6","article-title":"The measurement of cold sensitivity of the hand","volume":"16","author":"McCabe","year":"1991","journal-title":"J\u00a0Hand Surg Am"},{"issue":"2","key":"10.1016\/j.berh.2021.101684_bib56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.mvr.2011.05.007","article-title":"Sample entropy of laser Doppler flowmetry signals increases in patients with systemic sclerosis","volume":"82","author":"Figueiras","year":"2011","journal-title":"Microvasc Res"},{"issue":"4","key":"10.1016\/j.berh.2021.101684_bib57","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar3112","article-title":"Comparison of laser Doppler imaging, fingertip lacticemy test, and nailfold capillaroscopy for assessment of digital microcirculation in systemic sclerosis","volume":"12","author":"Correa","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2021.101684_bib58","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3899\/jrheum.141437","article-title":"Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomenon and systemic sclerosis: a comparison using the Raynaud condition score diary","volume":"42","author":"Pauling","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"3 Suppl 29","key":"10.1016\/j.berh.2021.101684_bib59","first-page":"S42","article-title":"Assessment of disease severity and prognosis","volume":"21","author":"Medsger","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2021.101684_bib60","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5301\/jsrd.5000198","article-title":"Systemic sclerosis trial design moving forward","volume":"1","author":"Johnson","year":"2016","journal-title":"J\u00a0Scleroderma Relat Disord"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:21:55Z","timestamp":1761499315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1521694221000267"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101684","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum toxin in the management of primary and secondary Raynaud's phenomenon","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101684"}}